Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2497
[2.]
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Arch Intern Med, 148 (1998), pp. 36-69
[3.]
Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
JAMA, 269 (1993), pp. 3015-3023
[4.]
A.M. Gotto.
Rationale for the management of dyslipidemia.
Contemporary diagnosis and management of lipid disorders, pp. 9-26
[5.]
J.L. Wiztum.
Drugs used in the treatment of hyperlipoproteinemias.
Contemporary diagnosis and management of lipid disorders, pp. 875-897
[6.]
D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, et al.
The nuclear receptor superfamily: the second decade.
Cell, 83 (1995), pp. 835-859
[7.]
V. Giguere.
Orphan nuclear receptors: from gene to function.
Endocr Rev, 20 (1999), pp. 689-725
[8.]
A. Chawla, J.J. Repa, R.M. Evans, D.J. Mangelsdorf.
Nuclear receptors and lipid physiology: opening the X-files.
Science, 294 (2001), pp. 1866-1870
[9.]
B. Desvergne, W. Wahli.
Peroxisome proliferator-activated receptors: nuclear control of metabolism.
Endocr Rev, 20 (1999), pp. 649-688
[10.]
I.P. Torra, G. Chinetti, C. Duval, J.C. Fruchart, B. Staels.
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice.
Curr Opin Lipidol, 12 (2001), pp. 245-254
[11.]
D.J. Peet, B.A. Janowski, D.J. Mangelsdorf.
The LXRs: a new class of oxysterol receptors.
Curr Opin Genet Dev, 8 (1998), pp. 571-575
[12.]
H. Tu, A.Y. Okamoto, B. Shan.
FXR, a bile acid receptor and biological sensor.
Trends Cardiovasc Med, 10 (2000), pp. 30-35
[13.]
F. Rastinejad.
Retinoid X receptor and its partners in the nuclear receptor family.
Curr Opin Struct Biol, 11 (2001), pp. 33-38
[14.]
J.C. Fruchart, B. Staels, P. Duriez.
The role of fibric acids in therosclerosis.
Curr Atheroscler Rep, 3 (2001), pp. 83-92
[15.]
B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, J.C. Fruchart.
Mechanism of action of fibrates on lipid and lipoprotein metabolism.
Circulation, 98 (1998), pp. 2088-2093
[16.]
S. Mudaliar, R.R. Henry.
New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers.
Annu Rev Med, 52 (2001), pp. 239-257
[17.]
F.M. Martens, F.L. Visseren, J. Lemay, E.J. De Koning, T.J. Rabelink.
Metabolic and additional vascular effects of thiazolidinediones.
Drugs, 62 (2002), pp. 1463-1480
[18.]
A.A. Parulkar, M.L. Pendergrass, R. Granda-Ayala, T.R. Lee, V.A. Fonseca.
Nonhypoglycemic effects of thiazolidinediones.
Ann Intern Med, 134 (2001), pp. 61-71
[19.]
A.M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, M.R. Briggs, J.R. Paterniti, J.C. Fruchart, et al.
Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 1756-1764
[20.]
G. Chinetti, S. Lestavel, V. Bocher, A.T. Remaley, B. Neve, I.P. Torra, et al.
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.
Nat Med, 7 (2001), pp. 53-58
[21.]
P.J. Boyle, A.B. King, L. Olansky, A. Marchetti, H. Lau, R. Magar, et al.
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Clin Ther, 24 (2002), pp. 378-396
[22.]
M.A. Khan, J.V. St Peter, J.L. Xue.
Prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Diabetes Care, 25 (2002), pp. 708-711
[23.]
A.C. Li, K.K. Brown, M.J. Silvestre, T.M. Willson, W. Palinski, C.K. Glass.
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
J Clin Invest, 106 (2000), pp. 523-531
[24.]
H. Koshiyama, D. Shimono, N. Kuwamura, J. Minamikawa, Y. Nakamura.
Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.
J Clin Endocrinol Metab, 86 (2001), pp. 3452-3456
[25.]
J.M. Peters, S.S. Lee, W. Li, J.M. Ward, O. Gavrilova, C. Everett, et al.
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta.
Mol Cell Biol, 20 (2000), pp. 5119-5128
[26.]
W.R. Oliver Jr., J.L. Shenk, M.R. Snaith, C.S. Russell, K.D. Plunket, N.L. Bodkin, et al.
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.
Proc Natl Acad Sci USA, 98 (2001), pp. 5306-5311
[27.]
D.W. Russell.
Nuclear orphan receptors control cholesterol catabolism.
Cell, 97 (1999), pp. 539-542
[28.]
J.J. Repa, D.J. Mangelsdorf.
The role of orphan nuclear receptors in the regulation of cholesterol homeostasis.
Annu Rev Cell Dev Biol, 16 (2000), pp. 459-481
[29.]
B.A. Janowski, P.J. Willy, T.R. Devi, J.R. Falck, D.J. Mangelsdorf.
An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha.
Nature, 383 (1996), pp. 728-731
[30.]
M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, A. Luk, et al.
Identification of a nuclear receptor for bile acids.
Science, 284 (1999), pp. 1362-1365
[31.]
T.T. Lu, J.J. Repa, D.J. Mangelsdorf.
Orphan nuclear receptors as eLi- XiRs and FiXeRs of sterol metabolism.
J Biol Chem, 276 (2001), pp. 37735-37738
[32.]
D.J. Peet, S.D. Turley, W. Ma, B.A. Janowski, J.M. Lobaccaro, R.E. Hammer, et al.
Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha.
Cell, 93 (1998), pp. 693-704
[33.]
J.J. Repa, S.D. Turley, J.A. Lobaccaro, J. Medina, L. Li, K. Lustig, et al.
Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.
Science, 289 (2000), pp. 1524-1529
[34.]
B.A. Laffitte, J.J. Repa, S.B. Joseph, D.C. Wilpitz, H.R. Kast, D.J. Mangelsdorf, et al.
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes.
Proc Natl Acad Sci USA, 98 (2001), pp. 507-512
[35.]
Y. Luo, A.R. Tall.
Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element.
J Clin Invest, 105 (2000), pp. 513-520
[36.]
J.J. Repa, K.E. Berge, C. Pomajzl, J.A. Richardson, H. Hobbs, D.J. Mangelsdorf.
Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta.
J Biol Chem, 277 (2002), pp. 18793-18800
[37.]
J.R. Schultz, H. Tu, A. Luk, J.J. Repa, J.C. Medina, L. Li, et al.
Role of LXRs in control of lipogenesis.
Genes Dev, 14 (2000), pp. 2831-2838
[38.]
J.J. Repa, G. Liang, J. Ou, Y. Bashmakov, J.M. Lobaccaro, I. Shimomura, et al.
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta.
Genes Dev, 14 (2000), pp. 2819-2830
[39.]
S.B. Joseph, E. McKilligin, L. Pei, M.A. Watson, A.R. Collins, B.A. Laffitte, et al.
Synthetic LXR ligand inhibits the development of atherosclerosis in mice.
Proc Natl Acad Sci USA, 99 (2002), pp. 7604-7609
[40.]
C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, F.J. González.
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.
Cell, 102 (2000), pp. 731-744
[41.]
H.R. Kast, C.M. Nguyen, C.J. Sinal, S.A. Jones, B.A. Laffitte, K. Reue, et al.
Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.
Mol Endocrinol, 15 (2001), pp. 1720-1738
[42.]
C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, F.J. González.
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.
Cell, 102 (2000), pp. 731-744
[43.]
N.L. Urizar, A.B. Liverman, D.T. Dodds, F.V. Silva, P. Ordentlich, Y. Yan, et al.
A natural product that lowers cholesterol as an antagonist ligand for FXR.
Science, 96 (2002), pp. 1703-1706
[44.]
G.V. Satyavati, C. Dwarakanath, S.N. Tripathi.
Experimental studies on the hypocholesterolemic effect of Commiphora mukul. Engl. (Guggul.
Indian J Med Res, 57 (1969), pp. 1950-1962
[45.]
R.C. Agarwal, S.P. Singh, R.K. Saran, S.K. Das, N. Sinha, O.P. Asthana, et al.
Clinical trial of gugulipid — a new hypolipidemic agent of plant origin in primary hyperlipidemia.
Indian J Med Res, 84 (1986), pp. 626-634
[46.]
S. Nityanand, J.S. Srivastava, O.P. Asthana.
Clinical trials with gugulipid. A new hypolipidaemic agent.
J Assoc Physicians India, 37 (1989), pp. 323-328
[47.]
R. Mukherjee, J. Strasser, L. Jow, P. Hoener, J.R. Paterniti Jr., R.A. Heyman.
RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo.
Arterioscler Thromb Vasc Biol, 18 (1998), pp. 272-276
[48.]
J.M. Lenhard, M.E. Lancaster, M.A. Paulik, J.E. Weiel, J.G. Binz, S.S. Sundseth, et al.
The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction.
Diabetologia, 42 (1999), pp. 545-554
[49.]
T. Claudel, M.D. Leibowitz, C. Fievet, A. Tailleux, B. Wagner, J.J. Repa, et al.
Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.
Proc Natl Acad Sci USA, 98 (2001), pp. 2610-2615
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.